AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Receives Consensus Recommendation of "Hold" from Brokerages

Barsaba Taglieri
Agosto 12, 2017

"(AMAG) Upgraded at Zacks Investment Research" was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze.

Several large investors have recently made changes to their positions in AMAG. AMAG Pharmaceuticals posted sales of $143.78 million during the same quarter last year, which would suggest a positive year over year growth rate of 17%. Next quarter's EPS is forecasted at $0.29 with next year's EPS anticipated to be $-1.60. With 1.08M avg volume, 8 days are for Amag Pharmaceuticals Incorporated (NASDAQ:AMAG)'s short sellers to cover AMAG's short positions. (NASDAQ:AMAG). 16,462 are held by Matarin Cap Mngmt Lc. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm had revenue of $158.39 million for the quarter, compared to analysts' expectations of $158.83 million. During the same quarter in the previous year, the company posted $1.45 EPS. The business's revenue for the quarter was up 24.3% on a year-over-year basis. The stock of AMAG Pharmaceuticals, Inc. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $25.57. Cantor Fitzgerald reiterated a "hold" rating and set a $23.00 price target on shares of AMAG Pharmaceuticals in a research report on Tuesday, May 2nd. ValuEngine lowered AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, May 11th. Jefferies Group LLC set a $40.00 price objective on AMAG Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, April 20th. Tiaa Cref Investment Management LLC added to its ownership by buying 49,209 shares an increase of 39.7% as of 06/30/2017. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company's stock. AMAG Pharmaceuticals has an average rating of "Hold" and a consensus price target of $28.09.

COPYRIGHT VIOLATION WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of worldwide trademark and copyright laws. The value of the total investment in AMAG Pharmaceuticals, Inc. decreased from $859,000 to $761,000 a change of 11.4% quarter to quarter.

In other news, SVP Julie Krop sold 4,938 shares of the business's stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $20.00, for a total value of $98,760.00. Following the sale, the senior vice president now directly owns 28,336 shares of the company's stock, valued at $566,720. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Falcon Point Capital Llc sold 79,082 shares as the company's stock declined 21.74% while stock markets rallied. Falcon Point Capital Llc who had been investing in Amag Pharmaceuticals Inc. for a number of months, seems to be less bullish one the $595.49M market cap company. About shares traded. AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Thursday, August 3rd. (AMAG) by 22.5%. Its investment was valued at $1,698,000 a decrease of 0.1% as of the end of the quarter. Moreover, Employees Retirement Association Of Colorado has 0% invested in AMAG Pharmaceuticals, Inc. Wellington Management Group LLP now owns 161,739 shares of the specialty pharmaceutical company's stock worth $3,648,000 after buying an additional 113,240 shares during the period. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company's stock valued at $181,000 after buying an additional 554 shares during the last quarter.

AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 2.09% during midday trading on Tuesday, hitting $17.10. Shares saw a steep decrease in trading volume of 29.83% under the normal average daily volume.

Company chares are trading at $16.75 much lower than the 50 day moving average of $19.09 and impressively lower than the 200 day moving average of $20.86. The firm has "Hold" rating by BMO Capital Markets given on Wednesday, June 21. Voloridge Invest Management Ltd Co invested 0.08% of its portfolio in AMAG Pharmaceuticals, Inc. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Company has a portfolio of products and services with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Altre relazioni OverNewsmagazine

Discuti questo articolo